资本·大事1林清轩冲刺港交所5月29日,上海林清轩生物科技股份有限公司(以下简称“林清轩”)正式向港交所递交招股说明书,拟主板挂牌上市,中信证券和华泰国际担任联席保荐人。2022年至2024年,林清轩营收分别为6.91亿元、8.05亿元和12.10亿元,复合年增长率为32.5%。2023年,林清轩实现扭亏为盈,2024年的经调整净利润超2亿元。林清轩成立于2003年,聚焦抗皱紧致类护肤品市场。专注...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.